The first stop for professional medicines advice

Patient Group Directions, Administering, Supply

10 results

Applied filters

Administration of contrast agents under a PGD by multiple HCPs

15 July 2024Whether a healthcare professional (HCP) can prepare and/or administer contrast supplied by another HCP under a PGD will depend on a range of factors.

Supply and/or administration of Controlled Drugs under a PGD

16 November 2021The legal position on the supply and/or administration of controlled drugs under Patient Group Directions is summarised

Unlicensed medicines and use of PGDs

16 November 2021This page explains why PGDs are not a legal mechanism for the administration or supply of unlicensed medicines.

Using a Patient Group Direction to adjust doses of medicines

16 November 2021This article outlines why PGDs cannot be used to adjust the dosage of a medicine already in an individual's possession.

Off label medicine use under a Patient Group Direction

10 June 2021This article explains the legislation and guidance on the use of PGDs when a medicine is to be used outside its licence ('off-label').

Including medicines with Risk Minimisation Measures (RMM) in PGDs

16 March 2021Medicines with RMM may not be suitable for inclusion within Patient Group Directions (PGDs). If used, the RMM must be stated within the PGD.

Patient Group Directions (PGDs) and abortifacients

14 September 2020This article advises on the legal position on the supply/administration of abortifacients under PGDs.

Mixing of medicines and Patient Group Directions

9 September 2020This article provides advice on the legal considerations required when considering mixing medicines to be supplied or administered under a PGD

Patient Group Direction use in End of Life Care

10 August 2020Considerations required before implementing Patient Group Directions (PGDs) in End of Life Care.

Off-label or unlicensed product use under HMR 2012 exemptions

8 January 2020A legal position summary regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the Human Medicines Regulations 2012